Oral Oresentation 8

4:18 PM - 4:24 PM JST(7:18 AM - 7:24 AM UTC)

[O08-09] Long-term Efficacy and Safety of Tulisokibart in Patients with Crohn’s Disease (CD): Results From the Open-label Extension Period of the Phase 2 APOLLO-CD Study

*Wen Zhou¹, Corey A. Siegel², Rupert W. Leong³, Jaclyn K. Anderson¹, Mark Yen¹, Bin Dong¹, Bruce E. Sands⁴, Silvio Danese⁵, Brian G. Feagan⁶ (1. Merck & Co., Inc., Rahway, NJ, USA, 2. Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, 3. Concord Hospital and Macquarie University Hospital, Sydney, NSW, Australia, 4. Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 5. Humanitas Clinical and Research Center - IRCCS, Rozzano and Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, Italy, 6. Department of Medicine, Division of Gastroenterology, Western University, London, ON, Canada)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.